These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 12240781)

  • 1. Changes in tear function and the ocular surface after topical olopatadine treatment for allergic conjunctivitis: an open-label study.
    Dogru M; Ozmen A; Ertürk H; Sanli O; Karatas A
    Clin Ther; 2002 Aug; 24(8):1309-21. PubMed ID: 12240781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized, double-masked comparison of olopatadine ophthalmic solution, mometasone furoate monohydrate nasal spray, and fexofenadine hydrochloride tablets using the conjunctival and nasal allergen challenge models.
    Spangler DL; Abelson MB; Ober A; Gotnes PJ
    Clin Ther; 2003 Aug; 25(8):2245-67. PubMed ID: 14512132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the effects of ketotifen fumarate 0.025% and olopatadine HCl 0.1% ophthalmic solutions in seasonal allergic conjunctivities: a 30-day, randomized, double-masked, artificial tear substitute-controlled trial.
    Avunduk AM; Tekelioglu Y; Turk A; Akyol N
    Clin Ther; 2005 Sep; 27(9):1392-402. PubMed ID: 16291412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the effects of olopatadine ophthalmic solution, 0.2% on the ocular surface of patients with allergic conjunctivitis and dry eye.
    Mah FS; O'Brien T; Kim T; Torkildsen G
    Curr Med Res Opin; 2008 Feb; 24(2):441-7. PubMed ID: 18167176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the clinical efficacy and comfort of olopatadine hydrochloride 0.1% ophthalmic solution and nedocromil sodium 2% ophthalmic solution in the human conjunctival allergen challenge model.
    Butrus S; Greiner JV; Discepola M; Finegold I
    Clin Ther; 2000 Dec; 22(12):1462-72. PubMed ID: 11192137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the efficacy of olopatadine hydrochloride 0.1% ophthalmic solution and azelastine hydrochloride 0.05% ophthalmic solution in the conjunctival allergen challenge model.
    Spangler DL; Bensch G; Berdy GJ
    Clin Ther; 2001 Aug; 23(8):1272-80. PubMed ID: 11558863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, double-blind, parallel-group comparison of olopatadine 0.1% ophthalmic solution versus placebo for controlling the signs and symptoms of seasonal allergic conjunctivitis and rhinoconjunctivitis.
    Abelson MB; Turner D
    Clin Ther; 2003 Mar; 25(3):931-47. PubMed ID: 12852709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Double-masked, randomized, placebo-controlled clinical study of the mast cell-stabilizing effects of treatment with olopatadine in the conjunctival allergen challenge model in humans.
    Leonardi A; Abelson MB
    Clin Ther; 2003 Oct; 25(10):2539-52. PubMed ID: 14667955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the efficacy of combined fluticasone propionate and olopatadine versus combined fluticasone propionate and fexofenadine for the treatment of allergic rhinoconjunctivitis induced by conjunctival allergen challenge.
    Lanier BQ; Abelson MB; Berger WE; Granet DB; D'Arienzo PA; Spangler DL; Kägi MK
    Clin Ther; 2002 Jul; 24(7):1161-74. PubMed ID: 12182260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of the clinical efficacy of pheniramine maleate/naphazoline hydrochloride ophthalmic solution and olopatadine hydrochloride ophthalmic solution in the conjunctival allergen challenge model.
    Greiner JV; Udell IJ
    Clin Ther; 2005 May; 27(5):568-77. PubMed ID: 15978305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of the efficacy and tolerability of olopatadine hydrochloride 0.1% ophthalmic solution and cromolyn sodium 2% ophthalmic solution in seasonal allergic conjunctivitis.
    Katelaris CH; Ciprandi G; Missotten L; Turner FD; Bertin D; Berdeaux G;
    Clin Ther; 2002 Oct; 24(10):1561-75. PubMed ID: 12462286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the clinical efficacy and tolerability of olopatadine hydrochloride 0.1% ophthalmic solution and loteprednol etabonate 0.2% ophthalmic suspension in the conjunctival allergen challenge model.
    Berdy GJ; Stoppel JO; Epstein AB
    Clin Ther; 2002 Jun; 24(6):918-29. PubMed ID: 12117082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical efficacy of olopatadine vs epinastine ophthalmic solution in the conjunctival allergen challenge model.
    Lanier BQ; Finegold I; D'Arienzo P; Granet D; Epstein AB; Ledgerwood GL
    Curr Med Res Opin; 2004 Aug; 20(8):1227-33. PubMed ID: 15324525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. One-visit, randomized, placebo-controlled, conjunctival allergen challenge study of scanning and imaging technology for objective quantification of eyelid swelling in the allergic reaction with contralateral use of olopatadine and artificial tears.
    Abelson MB; Pratt S; Mussoline JE; Townsend D
    Clin Ther; 2003 Jul; 25(7):2070-84. PubMed ID: 12946551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of olopatadine 0.2% ophthalmic solution versus fluticasone furoate nasal spray for the treatment of allergic conjunctivitis.
    Rosenwasser LJ; Mahr T; Abelson MB; Gomes PJ; Kennedy K
    Allergy Asthma Proc; 2008; 29(6):644-53. PubMed ID: 19063816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loteprednol etabonate suspension 0.2% administered QID compared with olopatadine solution 0.1% administered BID in the treatment of seasonal allergic conjunctivitis: a multicenter, randomized, investigator-masked, parallel group study in Chinese patients.
    Gong L; Sun X; Qu J; Wang L; Zhang M; Zhang H; Wang L; Gu Y; Elion-Mboussa A; Roy L; Zhu B
    Clin Ther; 2012 Jun; 34(6):1259-1272.e1. PubMed ID: 22627057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An open-label, investigator-masked, crossover study of the ocular drying effects of two antihistamines, topical epinastine and systemic loratadine, in adult volunteers with seasonal allergic conjunctivitis.
    Ousler GW; Workman DA; Torkildsen GL
    Clin Ther; 2007 Apr; 29(4):611-6. PubMed ID: 17617284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Topical Olopatadine in the Treatment of Allergic Conjunctivitis: A Systematic Review and Meta-analysis.
    Kam KW; Chen LJ; Wat N; Young AL
    Ocul Immunol Inflamm; 2017 Oct; 25(5):663-677. PubMed ID: 27192186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of olopatadine and fluorometholone in contact lens-induced papillary conjunctivitis.
    Khurana S; Sharma N; Agarwal T; Chawla B; Velpandian T; Tandon R; Titiyal JS
    Eye Contact Lens; 2010 Jul; 36(4):210-4. PubMed ID: 20531202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Olopatadine: a drug for allergic conjunctivitis targeting the mast cell.
    Leonardi A; Quintieri L
    Expert Opin Pharmacother; 2010 Apr; 11(6):969-81. PubMed ID: 20307221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.